Biotech News
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb (BMY) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.
The source domain is bristol-myers-squibb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.
The original release is available below in a new tab so readers can continue into the full source when needed.